Tags

Type your tag names separated by a space and hit enter

Pneumococcal vaccination in splenectomised cancer patients.
Eur J Cancer. 2005 Aug; 41(12):1731-4.EJ

Abstract

Although pneumococcal vaccination has been recommended in splenectomised patients for more than 30 years, its use remains unsatisfactory. We conducted two consecutive retrospective assessments to determine the rate of pneumococcal vaccination among splenectomised cancer patients at a single institution. We found that 75% (82 of 115) of splenectomised cancer patients had received at least one documented pneumococcal vaccination as compared to only 59.7% of patients identified in a previous assessment conducted 1997. 20% (22 of 115) of the patients had not been vaccinated at all. Splenectomy was performed in 54% because of Hodgkin lymphoma. The pneumococcal vaccination coverage in this subgroup has risen from 40% in the previous assessment (1997) to 93% in the current survey. In conclusion, patients splenectomised at a young age because of Hodgkin lymphoma are the key group at risk for insufficient pneumococcal vaccination. Repeated assessments of the pneumococcal vaccination status increased the rate of vaccination.

Authors+Show Affiliations

Department of Medical Oncology, University Hospital, 3010 Bern, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16026979

Citation

Omlin, Aurelius G., et al. "Pneumococcal Vaccination in Splenectomised Cancer Patients." European Journal of Cancer (Oxford, England : 1990), vol. 41, no. 12, 2005, pp. 1731-4.
Omlin AG, Mühlemann K, Fey MF, et al. Pneumococcal vaccination in splenectomised cancer patients. Eur J Cancer. 2005;41(12):1731-4.
Omlin, A. G., Mühlemann, K., Fey, M. F., & Pabst, T. (2005). Pneumococcal vaccination in splenectomised cancer patients. European Journal of Cancer (Oxford, England : 1990), 41(12), 1731-4.
Omlin AG, et al. Pneumococcal Vaccination in Splenectomised Cancer Patients. Eur J Cancer. 2005;41(12):1731-4. PubMed PMID: 16026979.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pneumococcal vaccination in splenectomised cancer patients. AU - Omlin,Aurelius G, AU - Mühlemann,Kathrin, AU - Fey,Martin F, AU - Pabst,Thomas, PY - 2005/02/10/received PY - 2005/04/07/revised PY - 2005/04/08/accepted PY - 2005/7/20/pubmed PY - 2005/10/19/medline PY - 2005/7/20/entrez SP - 1731 EP - 4 JF - European journal of cancer (Oxford, England : 1990) JO - Eur. J. Cancer VL - 41 IS - 12 N2 - Although pneumococcal vaccination has been recommended in splenectomised patients for more than 30 years, its use remains unsatisfactory. We conducted two consecutive retrospective assessments to determine the rate of pneumococcal vaccination among splenectomised cancer patients at a single institution. We found that 75% (82 of 115) of splenectomised cancer patients had received at least one documented pneumococcal vaccination as compared to only 59.7% of patients identified in a previous assessment conducted 1997. 20% (22 of 115) of the patients had not been vaccinated at all. Splenectomy was performed in 54% because of Hodgkin lymphoma. The pneumococcal vaccination coverage in this subgroup has risen from 40% in the previous assessment (1997) to 93% in the current survey. In conclusion, patients splenectomised at a young age because of Hodgkin lymphoma are the key group at risk for insufficient pneumococcal vaccination. Repeated assessments of the pneumococcal vaccination status increased the rate of vaccination. SN - 0959-8049 UR - https://www.unboundmedicine.com/medline/citation/16026979/Pneumococcal_vaccination_in_splenectomised_cancer_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(05)00428-4 DB - PRIME DP - Unbound Medicine ER -